Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease

Cerebrospinal fluid (CSF) biomarkers have transformed the diagnosis and understanding of Alzheimer’s disease by providing direct measures of key pathological processes in the living brain. Core analytes include amyloid-β (Aβ) peptides, notably Aβ42 and Aβ40, whose altered concentrations reflect amyloid plaque formation, and tau proteins—both total tau (tTau) and phosphorylated tau (pTau)—which signal neurofibrillary tangle formation and neuronal injury. Advances in assay standardisation, including the use of reference proteins to adjust for inter-individual variability in total CSF protein levels, have reduced false positives and improved the sensitivity and specificity of existing markers. Ratios of Aβ42 to Aβ40 have emerged as superior to absolute Aβ42 values in discriminating Alzheimer’s pathology from other dementias by compensating for pre-analytical and analytical confounders. Together, these fluid biomarkers enable early detection of preclinical disease, stratification of patients for clinical trials, and monitoring of disease progression and response to therapy. Integration with imaging modalities such as amyloid positron emission tomography (PET) further refines diagnostic accuracy and offers complementary insights into regional brain pathology. As CSF biomarkers become embedded in routine memory-clinic practice worldwide, ongoing efforts focus on harmonising protocols, extending their utility in diverse populations and exploring novel analytes that capture synaptic dysfunction, neuroinflammation and proteomic signatures of disease subtypes.

Research from Nature Portfolio

A data-driven analysis has demonstrated that non-disease related variation in mean CSF protein levels can confound biomarker correlations and yield misleading associations. By identifying and validating stable reference proteins, researchers achieved more accurate normalisation of Aβ and tau measures, yielding improved sensitivity and specificity in diagnostic thresholds and attenuating false-positive findings. In a separate investigation, CSF levels of Aβ38 and Aβ40 were leveraged as surrogates of amyloidogenic processing of amyloid precursor protein. Higher CSF Aβ40 strongly correlated with cortical amyloid burden, particularly in individuals lacking the APOE ε4 allele, suggesting that increased Aβ production contributes to sporadic plaque accumulation. These insights offer mechanistic stratification markers and underscore the need to tailor therapeutic strategies according to individual Aβ production and clearance profiles.

Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease publication trend

The graph below shows the total number of articles in cerebrospinal fluid biomarkers in alzheimer’s disease across all publications each year (not limited to Nature Index journals).

Technical terms

Cerebrospinal fluid (CSF): Clear fluid surrounding the brain and spinal cord, sampled to measure central nervous system biomarkers.

Amyloid-β (Aβ): Peptides produced from amyloid precursor protein; aggregation of Aβ42 is central to plaque pathology.

Total tau (tTau) and phosphorylated tau (pTau): Microtubule-associated proteins whose elevated CSF levels indicate neuronal injury and tangle formation.

Aβ42/Aβ40 ratio: Proportion of the two main Aβ isoforms; normalises for inter-individual variability and improves diagnostic specificity.

Reference proteins: Stable CSF proteins used to adjust for overall protein concentration, reducing non-disease related variability.

Microfluidics: Technology for manipulating minute fluid volumes within microscale channels to concentrate and analyse biomarkers.

Immunoprecipitation–mass spectrometry (IP-MS): Technique combining antibody capture of target proteins with mass spectrometric detection for precise quantification.

References

1. Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases. Nature Communications (2024).
2. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. Alzheimer's Research & Therapy (2019).
3. Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis. Nature Communications (2016).
4. Magnetic separation and concentration of Aβ 1–42 molecules dispersed at the threshold concentration for Alzheimer’s disease diagnosis in clinically-relevant volumes of sample. Journal of Nanobiotechnology (2023).
5. Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease. Alzheimer's Research & Therapy (2023).
6. Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity. Translational Psychiatry (2024).